Phaseline

Companies › Hangzhou DAC Biotechnology

Hangzhou DAC Biotechnology: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DXC006
Recombinant humanized antibody-drug conjugate
–Phase 1Advanced Solid Tumors; Small Cell Lung CancerJun 2027
DEC003M–Phase 1Advanced Prostate CancerMar 2029
DXC008–Phase 1Prostate CancerApr 2030
DXC014–Phase 1Small Cell Lung CancerOct 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06224855DXC006Phase 1Advanced Solid TumorsOncologyJun 2027
NCT07559929DXC006Phase 1Small Cell Lung CancerOncologyJun 2028
NCT07657806DEC003MPhase 1Advanced Prostate CancerOncologyMar 2029
NCT06926283DXC008Phase 1Prostate CancerOncologyApr 2030
NCT07177937DXC014Phase 1Small Cell Lung CancerOncologyOct 2030

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.